Newsroom

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, een dochteronderneming van QIAGEN en marktleider op het gebied van schaalbare en toegankelijke single-cell-sequencing, heeft vandaag bekendgemaakt dat de Genomics Platform Core Facility van het Garvan Institute of Medical Research zich heeft aangesloten bij het Certified Service Provider (CSP)-programma. Deze samenwerking vergroot de toegang tot hoogwaardige, schaalbare single-cell-sequencing in heel Australië, de bredere Aziatisch-Pacifische regio e...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, une société QIAGEN et le chef de file du séquençage monocellulaire évolutif et accessible, annonce aujourd'hui que le site central de la plateforme génomique au sein du Garvan Institute of Medical Research a rejoint son programme de prestataires de services certifiés (CSP). Le partenariat élargit l'accès à un séquençage monocellulaire évolutif de haute qualité en Australie, dans l'ensemble de la région Asie-Pacifique et au-delà. Garvan est l'une des...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, un'azienda QIAGEN e il fornitore leader di soluzioni di sequenziamento di singole cellule scalabile e accessibile, oggi ha annunciato che la Genomics Platform Core Facility nel Garvan Institute of Medical Research ha aderito al suo Programma di Fornitori certificati di servizi (CSP). La collaborazione estende l'accesso al sequenziamento di singole cellule di alta qualità e scalabile in Australia, nella più ampia regione Asia-Pacifico e oltre. Garvan...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, una empresa de QIAGEN y líder en secuenciación unicelular escalable y accesible, anunció hoy la incorporación de la Genomics Platform Core Facility del Garvan Institute of Medical Research a su programa de proveedores de servicios certificados (Certified Service Provider, CSP). Esta alianza amplía el acceso a servicios de secuenciación unicelular escalables y de alta calidad en Australia, la región de Asia-Pacífico y otros mercados. El Garvan Institu...

西雅图--(BUSINESS WIRE)--(美国商业资讯)-- QIAGEN旗下公司、可扩展及普及型单细胞测序领域的领军企业Parse Biosciences今日宣布，Garvan Institute of Medical Research旗下的基因组学平台核心设施已加入其认证服务商（CSP）计划。这一合作伙伴关系将拓宽澳大利亚、整个亚太地区及其他地区获取高质量、可扩展单细胞测序技术的渠道。 Garvan位居澳大利亚最杰出医学研究机构之列，其基因组学平台在细胞分选、捕获和测序方面拥有深厚的专业经验。作为认证服务商，Garvan将为该地区的科研人员提Parse的Evercode WT试剂盒。Garvan Institute细胞基因组学负责人Chris O'Keeffe表示，“我们看到针对Parse项目的需求不断增长，并且发现该技术易于实施和运行，能够产生极佳的数据。” Parse Biosciences联合创始人兼首席技术官Charlie Roco表示，”Garvan是全球最受推崇的生物医学研究机构，我们非常荣幸地欢迎他们加入我们的认证服务商网络。我们的CSP 计划将研究人员与值得信赖...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, ein Unternehmen der QIAGEN-Gruppe und Marktführer im Bereich skalierbarer und zugänglicher Einzelzellsequenzierung, gab heute bekannt, dass die Genomics Platform Core Facility am Garvan Institute of Medical Research seinem Certified Service Provider (CSP)-Programm beigetreten ist. Die Partnerschaft erweitert den Zugang zu hochwertiger, skalierbarer Einzelzellsequenzierung in ganz Australien, im gesamten asiatisch-pazifischen Raum und darüber hinaus....

西雅圖--(BUSINESS WIRE)--(美國商業資訊)-- 可擴充且易於使用的單細胞定序領導廠商、QIAGEN旗下公司Parse Biosciences今日宣布，Garvan Institute of Medical Research的Genomics Platform Core Facility已加入其認證服務供應商(CSP)計畫。此次合作將擴大澳洲、整個亞太地區及其他地區獲取高品質、可擴充單細胞定序服務的管道。 Garvan是澳洲最頂尖的醫學研究機構之一，其Genomics Platform在細胞分選、細胞捕捉及定序方面擁有深厚經驗。成為認證服務供應商後，Garvan將為該地區研究人員提供Parse的Evercode WT試劑套組相關服務。Garvan Institute細胞基因體學負責人Chris O'Keeffe表示：「越來越多研究人員提出使用Parse平台的專案需求，而這項技術不僅容易導入與操作，更能產出高品質的資料。」 Parse Biosciences共同創辦人暨技術長Charlie Roco表示：「Garvan是全球最受推崇的生物醫學研究機構之一，我們非常榮幸歡迎...

SEATTLE--(BUSINESS WIRE)--A Parse Biosciences, empresa da QIAGEN e líder em sequenciamento de célula única escalável e acessível, anunciou hoje que o Laboratório Central da Plataforma de Genômica, do Garvan Institute of Medical Research, aderiu ao seu Programa de Prestadores de Serviços Certificados (CSP). A parceria amplia o acesso ao sequenciamento de células únicas de alta qualidade e escalável na Austrália, na região da Ásia-Pacífico e em outras localidades. O Garvan é uma das instituições...

NEW YORK--(BUSINESS WIRE)--GID, a vertically-integrated real estate owner, operator, developer and investor with $32.8 billion in assets under management, today announced the continued expansion of GID Residential Partners, its national development platform, with a strategic expansion in the Texas market. The initiative will be led by industry veteran Matt Miller, who joins the firm as Senior Managing Director. Building on GID's longstanding multifamily development experience, the formalized pr...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 17, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Sportradar Group AG (“Sportradar” or the “Company”) (NASDAQ: SRAD) Class A ordinary shares between November 7, 2024, and April 21, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO LOST MONEY ON SPORTRADAR GROUP AG (SRAD), CLICK HERE TO PARTICI...